in this issue
Regions :: Western Europe :: Switzerland
Lonza invests in single-use technology and facility upgrades for clinical ADC manufacturing
12:22 AM MDT | June 11, 2014 | Deepti Ramesh
Lonza says it is investing in technology and facility improvements to its antibody drug conjugate (ADC) clinical manufacturing facility at Visp, Switzerland. The planned upgrades include the introduction of single-use technology for flexible ADC manufacturing, along with a recently optimized plant layout and revamping, which has resulted in a larger ADC production area. The addition of single-use manufacturing systems will reduce potential product contamination risks and allow for increased manufacturing capacity of existing and novel ADC platforms, Lonza says...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee